Officials and industry officials said on Wednesday that the Drug Regulatory Authority of Pakistan (DRAP) has agreed to raise the maximum retail price (MRP) of paracetamol as a ‘hardship case’ after various drug manufacturers warned that they would be unable to manufacture the medicine at the current price due to rising raw material costs from China.
“The Drug Pricing Committee (DPC) of the DRAP has recommended some relief to paracetamol manufacturers because prices of its Active Pharmaceutical Ingredient (API) has increased manifolds in the international market,” a DRAP official said on condition of anonymity to The News.
